ArticleNutrition & metabolism2025
Serum chemerin levels and the risk of muscle health decline in geriatric population.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChemerin, an adipokine involved in adipogenesis and lipid metabolism, has been linked to various metabolic disorders. Given that metabolic dysregulation contributes to deterioration of muscle health and subsequent functional impairment, this investigation aimed to assess the utility of circulating chemerin levels as an indicator for the risk of muscle health decline among the elderly population.
methodsIndividuals aged 65 years and older dwelling in the community underwent routine health check-ups were recruited. Anthropometric parameters, habitual gait speed, and handgrip strength were measured. Enzyme-Linked Immunosorbent Assay was used for examining serum chemerin levels. Based on muscle mass and functional parameters, participants were classified as robust, presarcopenia, dynapenia, and sarcopenia. We applied logistic regression to evaluate the risks between specific muscle health conditions and serum chemerin levels. A quartile-based analysis was performed to assess trends in muscle health risk across varying serum chemerin levels.
resultsThe study included 433 participants, of whom 45.03% were male. The prevalence of dynapenia (25.40%) exceeded that of sarcopenia (17.09%). The concentrations of chemerin were higher in participants with dynapenia than in those with sarcopenia. Multivariate logistic regression disclosed a positive association between elevated serum chemerin levels and an increased risk of dynapenia (odds ratio = 1.012, 95% confidence interval = 1.002–1.021, p = 0.015). The quartile-based analysis further confirmed a dose-response relationship between chemerin levels and risk of dynapenia; the association continued to be significant after confounding variables adjustment (p for trend = 0.015).
conclusionsHigher serum chemerin levels were associated with greater risk of dynapenia in community-residing older people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.